Current Research Studies
Cancer – PLAT-02: A Phase 1/2 Feasibility and Safety Study of CD19-CAR T-Cell Immunotherapy for CD19+ Leukemia
What is the goal of this study?
Our researchers are testing T-cell therapy in children and young adults with non-Hodgkin lymphoma who are not likely to survive with current treatments. These trials are known as Pediatric Leukemia Adoptive Therapy (PLAT) studies.
Through the PLAT studies, researchers are working to answer these questions:
- Is T-cell therapy safe to give to children and young adults with relapsed or refractory acute leukemia or lymphoma?
- What is the largest dose that children and young adults can stand (the maximum tolerated dose)?
- Does T-cell therapy work against leukemia?
In PLAT-02, the CAR T cells are reprogrammed to recognize and target the CD19 protein expressed by most leukemia cells.
The first phase of PLAT-02 was important in establishing the safety of this experimental therapy, short-term side effects and the maximum dose of T cells.
Phase 2 began in June 2016 and is currently enrolling patients. It will demonstrate how this therapy works for a larger group of patients with non-Hodgkin lymphoma.
Who can join the study?
This study might be a good fit for children and young adults who:
- Are ages 1 to 26 years old
- Has relapsed or refractory CD19+ non-Hodgkin lymphoma. It is not open to young people with other leukemias or other childhood cancers.
Researchers use many other factors to decide whether a patient can take part in a study (inclusion criteria) or cannot take part (exclusion criteria). The study team at Seattle Children’s can explain what these factors mean for you or your child.
What will happen if my child takes part in this study?
You can read more about the PLAT-02 study at clinicaltrials.gov.
Who can I contact for more information?
Learn about other PLAT studies at Seattle Children's:
- PLAT-05: A Phase 1 Feasibility and Safety Study of Dual Specificity CD19 and CD22-CAR T-Cell Immunotherapy for CD19+CD22+ Leukemia and Lymphoma
- PLAT-07: A Phase 1/2 Study of CD22-Specific CAR T Cells for CD22+ Leukemia or Lymphoma